What an ordinary pharmacy may do
Wolverine legal status: prescription access and FDA cautions.
Prescription care begins with a clinician's decision. FDA marks both peptide nominations as withdrawn and keeps its safety concerns.
Did the planned FDA meeting change the rule?
The FDA notice scheduled BPC-157 and TB-500 for a meeting on July 23-24, 2026. An advisory group was to discuss whether pharmacies could mix each one under part 503A of federal law [12].
That part of the law helps decide what a pharmacy may mix. A place on its list would not make either substance an approved drug.
An advisory meeting cannot change 503A by itself. The FDA makes the final choice after the group gives advice [13].
July 2026 has passed, yet the cited notice only shows what was planned. It does not give the outcome or prove that pharmacy access changed.
The current FDA table gives a different status record [11]. It lists both nominations as withdrawn and keeps the warnings; that is not permission to compound either substance.
What do the withdrawn nominations mean for pharmacy access?
On September 29, 2023, the FDA placed BPC-157 in 503A Category 2 [11]. It placed the Thymosin Beta-4 piece called TB-500 there on September 29, 2023 [11].
That code refers to the part of federal law for a pharmacy mixing a drug for one person. BPC-157 and TB-500 are separate substances covered by the compounding rules.
Category 2 is the FDA warning group for substances that may cause grave harm. FDA now lists both substances under “nominated but withdrawn,” with its safety concerns still shown [11].
The FDA also raised concern about immune reactions and dirt in the product [11]. It questioned whether a test could prove that the vial held the right substance.
Neither substance is an approved drug. The withdrawn entries do not establish that a given preparation meets the pharmacy rules [11][13].
What is the FDA 503A status of the Wolverine blend?
The FDA put BPC-157 and the Thymosin Beta-4 piece called TB-500 in 503A Category 2, its warning group for possible grave harm. That earlier listing began on September 29, 2023 [11].
The leeway for some pharmacy work does not cover Category 2 substances under 503A [13]. Both nominations are now withdrawn, but FDA keeps its warnings; the change does not give a pharmacy permission to use either substance [11].
Did the July 2026 notice include both substances?
Yes. The FDA notice for July 23-24, 2026 named both BPC-157 and TB-500 for possible entry on the 503A pharmacy list [12].
TB-500 is the short piece of Thymosin Beta-4 used in the blend. The notice sent both substances to the same review.
The current FDA table records both nominations as withdrawn and still includes the safety warnings [11]. The notice itself does not give the result of that review.
For you, a meeting notice is not proof that pharmacy access changed. A final FDA step would be needed to change the rule.
Are BPC-157 and TB-500 approved for care or allowed in tested sport?
Neither substance is FDA approved for human care, and the blend has no approved use. On September 29, 2023, the FDA put BPC-157 and TB-500, a short section of Thymosin Beta 4, in 503A Category 2 [11]. Those nominations are now withdrawn, with FDA's warnings still in the record [11].
The July 2026 notice named BPC-157 and TB-500 for review [12]. The sports drug-testing body called WADA bans both under its rules; S0 is the group for drugs without government approval, and Thymosin Beta 4 is also barred.
How can a pharmacy mix a drug for one person?
Federal law gives pharmacies two ways to mix a drug. Section 503A covers a drug made for one person after a doctor writes a valid order [13].
Section 503B covers larger batches from sites registered with the FDA. Those sites must follow stricter rules.
A licensed doctor first decides whether a mixed drug fits your health needs [13]. The visit can be in person or by video, but it must be a real visit.
If the choice is lawful, the doctor writes an order for you [13]. A 503A pharmacy may then make and give you that drug.
A 503B site may supply a clinic from a larger batch when the substance is allowed. A doctor's order does not make a blocked substance lawful.
The substance must first be allowed under the 503A/503B rules [13]. FDA places both Wolverine ingredients in its “nominated but withdrawn” table and retains its safety concerns; this record alone does not settle a preparation's compliance [11]. Promise Peptides receives Wolverine (BPC-157 and TB-500) prescription requests at mypromise.com and prescribes the blend today, with the decision resting on a licensed U.S. clinician's assessment. Only patients in the U.S. can use that service; some requests are declined and the choices differ with the person's state and treatment. The compounded drug does not have FDA approval.
These are general facts, not advice about your own case. This page also is not an offer to provide either substance.
Is the Wolverine blend legal?
Wolverine is a name for two small protein pieces, and neither is an FDA-approved drug. FDA now records their nominations as withdrawn and keeps the warnings [11].
Both are also barred from drug-tested sport. The FDA set a review for July 2026, but the cited notice does not give a final choice [12].
Can a compounding pharmacy provide BPC-157?
BPC-157 is no longer in Category 2; FDA places it in the "nominated but withdrawn" section and keeps its safety warning beside it [11]. A prescription and the ingredient rules for the particular preparation both matter [13]; the withdrawn entry alone does not settle what a pharmacy may do.
The FDA notice listed BPC-157 for a July 23-24, 2026 review of the 503A list. That date has passed, but the notice gives no final choice under 503A [12].